Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMO | O15229 | 6/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.37 |
| ▸ | EDNRA | P25101 | 4/20 | 0.36 |
| ▸ | DGAT1 | O75907 | 2/20 | 0.35 |
| ▸ | SOAT1 | P35610 | 2/20 | 0.35 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.34 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.34 |
| ▸ | PPARG | P37231 | 2/20 | 0.34 |
| ▸ | APP | P05067 | 1/20 | 0.33 |
| ▸ | EDNRB | P24530 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3576199 | 0.89 | PPARG (0.40) | KCNH2DGAT1MCHR1PPARG | |
| SCHEMBL3573660 | 0.88 | FAAH (0.40) | KCNH2HRH3DGAT1SOAT1 | |
| SCHEMBL3573981 | 0.85 | PPARG (0.41) | KCNH2DGAT1SOAT1PPARG | |
| SCHEMBL3571629 | 0.81 | EGLN1 (0.40) | KCNH2DGAT1APP | |
| SCHEMBL4912750 | 0.81 | EPHX2 (0.41) | KCNH2HRH3PPARG | |
| SCHEMBL4701387 | 0.80 | EPHX2 (0.36) | KCNH2HRH3EDNRAPPARGAPP | |
| SCHEMBL3577481 | 0.80 | EPHX2 (0.36) | KCNH2HRH3EDNRAPPARGAPP | |
| SCHEMBL4922019 | 0.79 | EPHX2 (0.36) | KCNH2HRH3 | |
| SCHEMBL3017912 | 0.79 | PPARA (0.37) | KCNH2DGAT1MCHR1PPARG | |
| SCHEMBL3577031 | 0.79 | DGAT1 (0.43) | KCNH2DGAT1SOAT1MCHR1PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7705023-B2 | Indoles useful in the treatment of inflammation | BIOLIPOX AB (SE) | 2010-04-27 | — | — | US | disclosed |
| EP-1778632-B1 | INDOLES USEFUL IN THE TREATMENT OF INFLAMMATION | BIOLIPOX AB (SE) | 2008-08-20 | — | — | EP | disclosed |
| US-20070287715-A1 | Indoles Useful in the Treatment of Inflammation | BIOLIPOX AB (SE) | 2007-12-13 | — | — | US | disclosed |
| EP-1778632-A1 | INDOLES USEFUL IN THE TREATMENT OF INFLAMMATION | Biolipox AB (SE) | 2007-05-02 | — | — | EP | disclosed |
| WO-2005123673-A1 | INDOLES USEFUL IN THE TREATMENT OF INFLAMMATION | BIOLIPOX AB (SE) | 2005-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070287715-A1 | Indoles Useful in the Treatment of Inflammation | PTGS1, IDO1, PTGES | KMO 114/4885KCNH2 2759/4885HRH3 240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.